Genome-wide association studies have generally failed to identify polymorphisms associated with antidepressant response. Possible reasons include limited coverage of genetic variants that this study tried to address by exome genotyping and dense imputation. A meta-analysis of Genome-Based Therapeutic Drugs for Depression (GENDEP) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D) studies was performed at the single-nucleotide polymorphism (SNP), gene and pathway levels. Coverage of genetic variants was increased compared with previous studies by adding exome genotypes to previously available genome-wide data and using the Haplotype Reference Consortium panel for imputation. Standard quality control was applied. Phenotypes were symptom improvement and remission after 12 weeks of antidepressant treatment. Significant findings were investigated in NEWMEDS consortium samples and Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) for replication. A total of 7062 950 SNPs were analyzed in GENDEP (n = 738) and STAR*D (n = 1409). rs116692768 (P = 1.80e − 08, ITGA9 (integrin α9)) and rs76191705 (P = 2.59e − 08, NRXN3 (neurexin 3)) were significantly associated with symptom improvement during citalopram/escitalopram treatment. At the gene level, no consistent effect was found. At the pathway level, the Gene Ontology (GO) terms GO: 0005694 (chromosome) and GO: 0044427 (chromosomal part) were associated with improvement (corrected P = 0.007 and 0.045, respectively). The association between rs116692768 and symptom improvement was replicated in PGRN-AMPS (P = 0.047), whereas rs76191705 was not. The two SNPs did not replicate in NEWMEDS. ITGA9 codes for a membrane receptor for neurotrophins and NRXN3 is a transmembrane neuronal adhesion receptor involved in synaptic differentiation. Despite their meaningful biological rationale for being involved in antidepressant effect, replication was partial. Further studies may help in clarifying their role.
INTRODUCTION
Major depressive disorder (MDD) became one of the five leading diseases contributing to disability-adjusted life years in 2010 in the United States. 1 MDD is associated with a huge increase in suicide risk, 2 poor quality of life (comparable to that observed in severe physical disorders such as arthritis and heart disease 3 ) and health expenditure (direct costs alone amount to 42 billion dollars per year in Europe 4 ). Despite the availability of antidepressant drugs belonging to different classes, high interindividual variability is observed in response. The lack of reliable and reproducible markers of treatment outcome contributes to unsatisfactory response and remission rates as well as to side-effect burden, poor treatment adherence and early treatment discontinuation. 5 Following the observation that antidepressant response clusters in families, genetic variants were considered promising biomarkers to tailor antidepressant treatments and improve the prognosis of MDD. 6, 7 Genome-wide association studies (GWASs) were a promising tool to identify the polymorphisms involved in antidepressant response after the overall contradictory and nonreplicated findings of candidate gene studies. 8 However, GWAS results fell below expectations, with no genome-wide significant signal (P o 5e − 08) that was replicated in different samples. [9] [10] [11] [12] [13] [14] [15] Possible reasons for these disappointing results include: (1) limited coverage of genetic variants (for example,~500K common polymorphisms were originally analyzed in Sequenced Treatment Alternatives to Relieve Depression (STAR*D), Genome-Based Therapeutic Drugs for Depression (GENDEP) and Munich Antidepressant Response Signature (MARS) studies and~1.2 millions in the meta-analysis of these studies thanks to imputation, whereas~40 million polymorphisms are known to date thanks to sequencing studies [9] [10] [11] 12, 16 ; (2) limited sample size; (3) sample heterogeneity (for example, different subtypes of depression and severity, different antidepressants); and (4) analysis of common variants (minor allele frequency (MAF) 40.01) alone. Furthermore, previous GWAS meta-analyses focused on single marker analysis and pathway analysis was performed in single samples and not as meta-analysis among different samples. 12, 17 Considering these limitations, the current study aimed to:
(1) Increase the coverage of genetic variants by analyzing exonic polymorphisms and dense imputation; (2) Test for association with antidepressant response at the level of single-nucleotide polymorphism (SNPs), genes and pathways including both common and rare variants; (3) Reduce heterogeneity in treatment by analyzing patients treated with the same antidepressant, as performed previously (see, for example, Uher et al. 10 and Tansey et al. 17 ).
In addition to the discovery samples of GENDEP and STAR*D, two replication samples were available ((Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS) and Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS)).

MATERIALS AND METHODS Samples
GENDEP. The GENDEP project was a 12-week partially randomized openlabel pharmacogenetic study with two active treatment arms. A total of 867 patients with unipolar depression (ICD-10 (10th revision of the International Statistical Classification of Diseases and Related Health Problems) or DSM-IV (Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders) criteria) aged 19-72 years were recruited at nine European centers. Eligible participants were allocated to flexibledosage treatment with either escitalopram (10-30 mg daily, 499 subjects) or nortriptyline (50-150 mg daily, 368 subjects). Severity of depression was assessed weekly by the Montgomery-Asberg Depression Rating Scale (MADRS), 18 Hamilton Rating Scale for Depression (HRSD-17) 19 and Beck Depression Inventory (BDI). 20 Detailed information about the GENDEP study has been previously reported. 10 A total of 736 subjects had no missing phenotypes and covariates after quality control (see quality control details in 'Genotyping and imputation' section) and they were included in this study.
STAR*D.
The STAR*D study was the NIMH (National Institute of Mental Health)-funded study aimed to determine the effectiveness of different treatments for patients with MDD who have not responded to the first antidepressant treatment. Non-psychotic MDD (DSM-IV criteria) patients with age between 18 and 75 years were enrolled from primary care or psychiatric outpatient clinics. Severity of depression was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C16) 21 at baseline and at weeks 2, 4, 6, 9 and 12, whereas HRSD-17 was administered at each level entry and exit. All patients received citalopram in level 1 and the present study is based on level 1 data. A total of 1953 patients were included in the genetic study. Detailed description of the study design and population are reported elsewhere. 22 A total of 1409 subjects had no missing phenotypes and covariates after quality control (see quality control details in 'Genotyping and imputation' section) and they were included in this study.
Replication samples. NEWMEDS consortium (http://www.newmeds-eur ope.com) 23 samples other than GENDEP 17 and PGRN-AMPS (Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study) sample 14 were used for replication of significant findings obtained in the GENDEP-STAR*D meta-analysis.
As part of the NEWMEDS consortium (for further details see Tansey et al.
17
), three studies conducted by academic institutions (GENDEP, see above; GENPOD, a randomized controlled trial of two active antidepressants (n = 601); 24 and GODS, a treatment cohort of severe depression (n = 131) 25 ) and two studies by pharmaceutical industry members of the European Federation of Pharmaceutical Industries and Associations (active comparator arms from randomized controlled trials by Pfizer, n = 355, and GlaxoSmithKline, n = 191) were combined. All included patients were diagnosed with MDD and treated for 6 to 12 weeks with either an antidepressant that acts primarily through blocking the reuptake of serotonin (selective serotonin reuptake inhibitors: escitalopram, citalopram, paroxetine, sertraline, fluoxetine) or an antidepressant that acts primarily through blocking the reuptake of norepinephrine (norepinephrine reuptake inhibitors: nortriptyline, reboxetine); see Tansey et al. 17 for details. A total of 980 subjects had no missing phenotypes and covariates after quality control (see quality control details in the 'Genotyping and imputation' section) and they were included in this study.
PGRN-AMPS included 529 participants with nonpsychotic MDD who were recruited at the Mayo Clinic in Rochester, Minnesota, primarily through the inpatient and outpatient practices of the Department of Psychiatry and Psychology. Participants were offered an 8-week course of treatment with either citalopram or escitalopram and depressive symptoms were rated using QIDS-C16 as in the STAR*D study in addition to the HRSD-17. For further details see Ji et al.
14 A total of 492 subjects had no missing phenotypes and covariates after quality control (see quality control details inthe 'Genotyping and imputation' section) and they were included in this study.
Outcomes
The primary outcome of this study was depressive symptom improvement after 12 weeks of antidepressant treatment. Continuous measures, such as percentage improvement, capture more information and have higher power than cutoff-based dichotomous measures, such as remission, but remission was associated with MDD prognosis. 26, 27 The percentage change in scores between baseline and 12 weeks was used to measure symptom improvement, using MADRS in the GENDEP study, and QIDS-C16 in STAR*D, as in previous studies in these samples. 10, 28 As a secondary outcome, we investigated symptom remission after 12 weeks of antidepressant treatment. According to standard criteria, remission was defined as HRSD-17 of ⩽ 7 (ref. Each outcome measure (percentage change, remission) was analyzed separately in GENDEP and STAR*D, and then a meta-analysis performed. Two analyses were performed, initially using all samples, and then including only escitalopram-treated patients from GENDEP, as escitalopram is the active isomer of citalopram, 33 the antidepressant used in STAR*D level 1.
Missing data were handled as in previous studies on the investigated samples. 9, 10 When at least one post-baseline assessment was available, the percentage improvement at 12 weeks was estimated as the best unbiased estimate of mixed-effect linear models. Participants without any postbaseline measurement were excluded from the analyses. As specific antidepressant response is associated with depression severity, 34 a minimum depression severity score of 14 on the HRSD-17 was an inclusion criterion in the STAR*D study (all the subjects that we included satisfied this criterion) but not in GENDEP, and thus a sensitivity analysis excluding GENDEP subjects with HRSD-17 of o14 was performed for the validation of significant findings.
Genotyping and imputation
Genome-wide data available in STAR*D were obtained using Affymetrix Human Mapping 500K Array Set in 969 subjects and Affymetrix GenomeWide Human SNP Array 5.0 (Affymetrix, South San Francisco, CA, USA) in the remaining 979 samples whereas in GENDEP Illumina Human610-quad bead chip (Illumina, San Diego, CA, USA) was used. 9, 10 In STAR*D the two groups genotyped by different arrays were balanced by ethnic grouping, gender and proportions of responders and nonresponders. Twelve samples were genotyped on both the 500K and 5.0 Arrays, and 499% concordance was found across these platforms. 9 Further genotyping in both samples was performed by the Illumina Infinium Exome-24 v1.0 BeadChip that includes~250K variants. Pre-imputation quality control was performed according to the following criteria: (1) variants with missing rate ⩾ 5%; (2) monomorphic variants; (3) subjects with genotyping rate o 97%; (4) subjects with gender discrepancies; (5) subjects with abnormal heterozygosity; (6) related subjects (identity by descent 40.1875); 35 (7) population outliers according to Eigensoft analysis of linkagedisequilibrium-pruned genetic data; 36, 37 (8) GWAS discordant subjects (referred to exome data only), and (9) non-white subjects (referred to STAR*D only as all subjects included in the GENDEP are of Caucasian ethnicity). Hardy-Weinberg equilibrium was not used as an exclusion criterion for markers (as previously done in the same data sets 17 ), as departures from Hardy-Weinberg equilibrium are expected in a case-only study. 38 Data were imputed using Minimac3 as provided by the Michigan imputation Server (https://imputationserver.sph.umich.edu/start.html). Post-imputation quality control was performed pruning variants according to the following criteria: (1) poor imputation quality (R 2 o0.30) 39,40 and (2) MAF o0.01 (see further details in 'Statistical analysis').
For a flowchart describing pre-and post-imputation quality control on each data set, see Supplementary Figure 1 . As exome array data were available only for 1015 subjects from the STAR*D sample (after quality control), the imputation of these data was performed separately from the imputation of genome-wide array data (1470 subjects).
Statistical analysis
We performed a fixed-effects meta-analysis to test the association between single polymorphisms and phenotypes using PLINK. 41 Heterogeneity measures (Cochrane's Q statistic and the I 2 heterogeneity index) were calculated. We tested linear or logistic regression models including the ancestry-informative principal components, recruitment centre, age and baseline severity as covariates in line with previous publications on these samples. 10, 12, 42 The same covariates were used for gene and pathway analysis.
We tested the association between genes and phenotypes as well as pathways and phenotypes using MAGMA. 43 MAGMA performs both a selfcontained and a competitive gene-set analysis; the latter is more conservative and it was applied in this study as it reflects the difference in association between genes in the pathway and genes outside the pathway. Only for the replication analyses self-contained analysis results were also reported as the replication nature of these tests. Both rare (MAF o0.01) and common variants were included in gene and pathway analysis, but only genotyped rare variants were retained whereas imputed rare variants were excluded. Indeed, imputation quality of rare variants using the Haplotype Reference Consortium panel was found to be better than using 1000 Genomes data (R 2 = 0.64 vs R 2 = 0.36 at MAF = 0.1% when using a 1M SNP chip) but we preferred to be conservative. 44 Thus, we chose a relatively conservative approach, including only subjects genotyped on both genome-wide and exome array in the gene and pathway analysis. In the gene-and pathway-level meta-analysis different weights were assigned to polymorphisms according to their MAF, and thus higher weight was assigned to rare variants as implemented in MAGMA. 43 For pathway analysis in each data set and their meta-analysis, the reported results refer to a competitive gene-set analysis that uses a conditional model to correct for confounding due to gene size, gene density and (if applicable) differences in sample size per gene. 43 The analyzed pathways were downloaded from http://software.broadinstitute. org/gsea/downloads.jsp (Biocarta, KEGG, Gene Ontology, Reactome, microRNA targets and transcription factor targets).
An attempt to replicate significant results was performed in NEWMEDS (omitting GENDEP) and PGRN-AMPS. In NEWMEDS phenotypes and covariates were as described in a previous study. 17 Briefly, percent symptom improvement at end point was adjusted for covariates (age, gender, baseline severity, ancestry-informative principal components and center in case of multicentric studies) and z-score transformed. Samples were genotyped on Illumina Human610-Quad BeadChips or Illumina Human660W-Quad BeadChips.
For PGRN-AMPS, details about phenotypes and covariates have been described elsewhere.
14 Percent symptom improvement at end point was used as phenotype and covariates were the first four population principal components and age as in the original GWAS. 14 Samples were genotyped on Illumina Human610-Quad BeadChips (Illumina).
In both replication samples we performed genotype imputation using the same method applied in GENDEP and STAR*D; pre-and postimputation quality control were performed according to the same criteria. For replication of individual SNP results, the index SNP and those in linkage disequilibrium (LD; R 2 ⩾ 0.30) were considered.
Multiple-testing correction and power analysis
For individual SNP analysis, a genome-wide significance threshold was set at P = 5e − 08. A suggestive significance threshold was set at a P-value of 5e − 06 that is two orders of magnitude below the genome-wide significance level and approximately corresponds to a level at which one association per genome-wide analysis is expected by chance. 45 A nominal P-value of 0.05 was set for replication of significant findings in NEWMEDS and PGRN-AMPS as no genome-wide analysis was performed in these samples.
For MAGMA gene-level analysis, the false discovery rate correction was applied. For MAGMA pathway analysis, 50 000 permutations were performed to correct for multiple testing.
For a continuous outcome in the whole sample (n = 2145) and setting α = 5e − 08, we had 80% power to identify a SNP with an effect size (heritability) of 0.018, whereas in citalopram-escitalopram-treated sample (n = 1739), we had 80% power to identify an effect size of 0.022. 46 For a dichotomous phenotype in the whole sample and setting α = 5e − 08, we had 80% power to identify a risk allele with MAF = 0.06 and RR = 1.50, whereas in citalopram-escitalopram-treated sample we had 80% power to identify a risk allele with MAF = 0.07 and relative risk (RR) = 1.50.
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RESULTS
The clinical-demographic characteristics of the samples are reported in Supplementary Table 1 . A total of 2145 subjects (1409 and 736 from STAR*D and GENDEP, respectively) were included in the SNP-level meta-analysis, and 1828 of them were treated with citalopram or escitalopram. A total of 1739 (1003 and 736 from STAR*D and GENDEP, respectively) subjects were included in the gene and pathway meta-analysis, and 1422 of them were treated with citalopram or escitalopram.
SNP analysis results
The GENDEP and STAR*D meta-analysis included 7062 950 SNPs and showed no evidence of genomic inflation (λ-values were ⩽ 1.01, QQ plots are shown in Supplementary Figure 2) .
In the whole sample, no SNP reached the genome-wide significance threshold for association with symptom improvement or remission. Eighty SNPs, from 17 genomic regions, reached suggestive level of association (P o 5e − 06) (Supplementary Table 2 ).
In STAR*D and escGENDEP (GENDEP escitalopram) metaanalysis, rs116692768 (MAF = 0.033, β STAR*D = − 0.14, β escGENDEP = − 0.20, P = 1.87e − 08) and rs76191705 (MAF = 0.012, β STAR*D = − 0.26, β escGENDEP = − 0.23, P = 2.39e − 08) were significantly associated with symptom improvement (Figure 1 and Table 1 ). These SNPs are located within introns of the ITGA9 (integrin α9) and NRXN3 (neurexin 3) genes. Another NRXN3 SNP (rs79302561) was close to the significance threshold (P = 6.76e − 08). There was no heterogeneity as measured by I 2 for these three SNPs, and thus fixed-effects and random-effects Pvalues corresponded. Each SNP was imputed, with R 2 values of over 0.6 for each SNP in each cohort (Table 1) . These SNPs retained significance after the exclusion of GENDEP patients with baseline HRSD-17 of o 14 (P = 2.69e − 08 and 3.43e − 08, respectively). Regional association plots for ITGA9 and NRXN3 genes are reported in Figure 2 . An overview of SNPs with suggestive level of association (P o 5e − 06) with symptom improvement in STAR*D and escGENDEP is reported in Supplementary Table 3 .
In the analysis of remission, no SNPs reached significance in the full meta-analysis or the meta-analysis with escGENDEP; SNPs with suggestive level of association (P o 5e − 06) are reported in Supplementary Tables 4 and 5 .
Gene analysis results
The gene-level analysis included 17 996 genes with 3 185 134 SNPs, and a schematic representation of this analysis is reported in Supplementary Figure 3a .
In the whole-sample meta-analysis, the olfactory receptor family 4 subfamily K member 2 (OR4K2) gene was associated with symptom improvement after multiple-testing correction (nominal P = 2.13e − 06, corrected P = 0.038 (false discovery rate)). OR4K2 included four rare genotyped SNPs in both data sets but the overall effect of OR4K2 rare alleles on improvement was in the opposite direction between the samples. GENDEP subjects carrying rare alleles (rs199718838 A, rs116972349 A, rs151057533 C and rs147651981 T, n = 8 subjects) showed lower mean symptom improvement (18.58 ± 53.43%) compared with common allele carriers (59.78 ± 24.49%), whereas in STAR*D the opposite was found (14 subjects carrying rare alleles (rs199718838 A, rs116972349 A, rs142549715 A and rs150417989 G) had a mean improvement of 70.30 ± 22.23% compared with a mean improvement of 50.33 ± 32.98% in common allele carriers). No gene survived multiple-testing correction in the analysis of remission (Supplementary Table 6 ).
In the meta-analysis of STAR*D and escGENDEP, no gene was associated with symptom improvement or remission (Supplementary Table 7 ). Several genes with nominal P ⩽ 0.0005 overlapped with those found in the whole sample, such as POU1F1, PAG1, PKM, RPUSD3 and PARP6.
Pathway analysis results
In this analysis, 17 996 genes including 3 185 134 SNPs were included, and a schematic representation of this analysis is reported in Supplementary Figure 3b .
In the whole sample, the Gene Ontology (GO) term corresponding to the chromosome pathway (GO: 0005694) and the chromosomal part (GO: 0044427) pathway were associated with symptom improvement (corrected P = 0.007 and 0.045, respectively). No pathway was associated with remission.
In STAR*D and escGENDEP, the steroid hormone receptor signaling pathway (GO: 0030518) was very close to the significance threshold for association with remission (corrected P = 0.055).
An overview of results is reported in Table 2 (including all pathways with P o 0.10) and the functional role of the variants in each of these pathways is shown in Supplementary Figure 4 . Interestingly, the chromosome pathway (GO: 0005694) was the richest in rare missense variants (6.6 versus 2.5-3% in the other pathways).
Replication samples
In both replication samples, only the genome-wide significant findings of STAR*D-escGENDEP meta-analysis and independent SNPs showing R 2 ⩾ 0.30 with them were analyzed. Second, pathways reported in Table 2 were also investigated. In NEWMEDS replication analyses were performed in the whole sample or only in subjects treated with some antidepressants according to results in the discovery samples. A total of 980 and 492 subjects were included after quality control in NEWMEDS and PGRN-AMPS, respectively.
In NEWMEDS the two SNPs associated with symptom improvement in the STAR*D-escGENDEP meta-analysis were not replicated and weak nominal associations were found for two SNPs (s7152916 and rs7152941) in LD with NRXN3 rs76191705 in the subsample treated with SSRIs (n = 751), whereas trends of association were found in the subsample treated with citalopram/escitalopram (n = 370) (Supplementary Table 8a ). In this sample only three independent SNPs in LD with the index SNPs were available.
Over 90% of SNPs included in the pathways showing significant associations (or trends, see Table 2 ) in the GENDEP-STAR*D metaanalysis were also available in NEWMEDS and only these pathways were analyzed in NEWMEDS. In the subsample treated with citalopram or escitalopram (n = 370), the intracellular receptormediated signaling pathway and the steroid hormone receptor signaling pathway were associated with improvement (permutated comparative P = 0.0028 and P = 0.017, respectively, self-P = 0.0089 and 0.014 (self-P-values are also reported because only six pathways were analyzed here and for a replication purpose, Table 2 did not show association with phenotypes. In PGRN-AMPS only ITGA9 rs116692768 and NRXN3 rs76191705 were investigated because no SNP showed LD ⩾ 0.30 with them. rs116692768 was associated with symptom improvement in the same direction to STAR*D-escGENDEP meta-analysis (P = 0.047, Supplementary Table 8b; no multiple-testing correction was applied here as only two SNPs were investigated for replication purpose), whereas rs76191705 showed no association with this phenotype (P = 0.34).
In PGRN-AMPS only the intracellular receptor-mediated signaling pathway and the steroid hormone receptor signaling pathway were analyzed because all patients were treated with citalopram or escitalopram in this sample. Over 90% of SNPs included in these pathways in STAR*D-escGENDEP meta-analysis was available in PGRN-AMPS, but no association with symptom improvement was found (nominal self-P-values were 0.10 and 0.11, respectively). 
DISCUSSION
Main findings
The present study has exploited existing pharmacogenetic samples (GENDEP and STAR*D), through: (1) the increase of genetic variant coverage (exome genotyping, high-density imputation) and (2) SNP-, gene-and pathway-level meta-analysis.
In the SNP-level meta-analysis, rs116692768 and rs76191705 were associated with symptom improvement during citalopram/ escitalopram treatment (Table 1) , rs116692768 was nominally replicated in PGRN-AMPS but none of the two SNPs was replicated in the remaining NEWMEDS samples. The effect sizes of these SNPs may appear relatively larger compared with those reported for other complex traits, consistently with the findings of other GWAS (the median effect size of pharmacogenomics variants was reported to be twice as large as that observed for associations with complex disease risk 48 ). These SNPs are located within ITGA9 and NRXN3, respectively. Both these SNPs are intronic, but the latter is a NMD (non-sense-mediated decay) transcript variant (that is, it is a target of NMD). NMD is a post-transcriptional surveillance process that recognizes and degrades mRNAs containing premature termination codons but it also targets 3-10% of normal transcripts in humans, thereby serving as a widespread gene regulatory mechanism.
49-51 rs79302561 T allele was reported to act as an enhancer of gene expression in several cell types (Ensembl GRCh37 release 84). ITGA9 rs143661452 lies within both ITGA9 and ITGA9-AS1 (antisense RNA). Antisense RNAs are involved in multiple regulatory processes in eukaryotes, such as transcriptional interference and RNA masking. 52 No regulatory role of rs143661452 is known so far.
The proteins coded by ITGA9 and NRXN3 show interesting functions in relation to antidepressant action. Integrins are heterodimeric (one α-and one β-subunit) transmembrane proteins that connect the extracellular environment to intracellular signaling. In the central nervous system they are involved in the control of synaptic plasticity, long-term potentiation, cell adhesion and migration. 53, 54 Polymorphisms in another β-isoform (ITGB3) and expression level of this gene have been associated with antidepressant response in humans. 42, 55 Neurexins are type I transmembrane neuronal adhesion receptors and their interaction with neuroligins is sufficient to trigger postsynaptic and presynaptic differentiation. 56 Non-genome-wide significant SNPs showing suggestive Pvalues ( o5e − 06) were mainly intergenic but several of them lie in genes previously reported to be involved in mood disorders or antidepressant response (particularly SORCS2, GRIN2D, CTNND2, CSGALNACT1, DISC1, TSNAX-DISC1).
57-66
The gene-level meta-analysis did not show any consistent finding. Indeed, the OR4K2 gene reached the significance threshold (Supplementary Table 6 ) but the effect of rare alleles on symptom improvement had opposite direction between GENDEP and STAR*D. Olfactory receptor genes have been shown to be overrepresented among homozygous loss-of-function genes and segregating polymorphisms of functional and nonfunctional copies of olfactory genes are common. 67 The olfactory receptor family is the most polymorphic family of genes in humans after the major histocompatibility complex and the phenotypic consequences of such genetic variability are not completely clear but likely not dramatic given their large diffusion. 68 Our pathway meta-analysis in GENDEP-STAR*D showed that the chromosome pathway (GO: 0005694) and the chromosomal part (GO: 0044427) pathway were associated with symptom improvement. These pathways were not associated with improvement in NEWMEDS, but GO: 0044427 and particularly GO: 0005694 were much richer in rare missense variants compared with the other significant pathways (Supplementary Figure 3) and this may have limited the replicability of the finding as no exome genotyping was performed in NEWMEDS. Interestingly, the Pharmacogenomics of antidepressant response C Fabbri et al chromosomal part pathway has been previously associated with antidepressant response by a genome-wide gene expression study. 69 Among the top genes of the chromosome and chromosomal part pathways (Table 2) , some are involved in the differentiation of neural stem cells into neurons (UPF1 (Regulator Of Nonsense Transcripts Homolog), HMGB1 (High Mobility Group Box 1) and neural development (FOXC1 (Forkhead Box C1) [70] [71] [72] ). Thus, these genes may play a role in the neurogenesis process that is known to mediate the effect of antidepressants. Another member of these pathways is PAM (Peptidylglycine α-Amidating Monooxygenase) that acts as a regulator of amygdala excitability and synaptic plasticity 73 and consistently it plays a role in emotional responses regulation. 74 The meta-analysis of escGENDEP and STAR*D showed that the steroid hormone receptor signaling pathway and the intracellular receptor-mediated signaling pathway (that largely overlap between each other) were close to the significance threshold after permutations. Impaired glucocorticoid receptor function has been suggested to be causal for hypothalamic-pituitary-adrenal axis hyperactivity in MDD that results in impaired neurogenesis and reduction of hippocampal volume. Antidepressants modulate the expression of glucocorticoid receptor, its translocation to the nucleus and also the transcription of its target genes. 75 The steroid hormone receptor signaling pathway and the intracellular receptor-mediated signaling pathway were associated with improvement in NEWMEDS citalopram-escitalopram-treated subsample but not in PGRN-AMPS. YWHAH was one of the top genes of this pathway found in both discovery sample and NEWMEDS. YWHAH codes for the η subtype of the 14-3-3 protein family, it is expressed mainly in the brain and it is a positive regulator in the glucocorticoid signal pathway by blocking the degradation of the glucocorticoid receptor. Variants in this genes have been associated with bipolar disorder and schizophrenia. 76 
Limitations
The limitations of the present study should be considered. First, the samples included in this study (particularly NEWMEDS samples used for replication) were heterogeneous from several points of view, for example, baseline severity, scales used to assess depressive symptoms, time points of evaluation, antidepressant treatment and dose and setting of recruitment. Heterogeneity across samples and small size of replication samples have limited the power to replicate our findings. In GENDEP and part of STAR*D exome genotypes were available (Illumina Infinium Exome-24 v1.0 BeadChip) but these were not genotyped in the replication samples, making it difficult to replicate the gene and pathway analysis findings. Antidepressant response is known to be a heterogeneous phenotype that is affected by a number of genetic and nongenetic variables. In this study we considered age, baseline severity, recruitment center and ancestry-informative principal components as covariates and we investigated genes and pathways as analysis units in addition to individual SNPs, but there are presumably a number of factors that we did not take into account, such as the effect of the environment. MDD was demonstrated to be genetically heterogeneous, as independent samples showed relatively low genetic correlation compared with schizophrenia and bipolar disorder. 77 The significant SNPs that we identified explained a limited percent of variance in symptom improvement (rs116692768 explained 3.5% and rs76191705 2.7% in escGENDEP, whereas both variants explained~1.4% of phenotypic variance in STAR*D), that is not expected to be clinically significant. Indeed, it has been suggested that a variant explaining 6.3% of variance may be considered as clinically meaningful. 78 Placebo response is another issue not taken into account by antidepressant pharmacogenomics trials, despite placebo response was reported to significantly contribute to the antidepressant effect and to have a relevant genetic component. 79 Finally, the replication of findings was weak or absent and no validation of the results was obtained through the use of complementary investigation strategies such as gene expression studies.
CONCLUSIONS
The increase in genetic variant coverage seems useful to identify new variants that may influence antidepressant efficacy, but the difficulty in signal replication across different samples is still a problem. Adequate sample size represents a primary issue to allow replication, but also the use of standardized criteria for patient inclusion, treatment and evaluation. The identification of more homogenous groups of patients appears a critical issue in MDD and antidepressant pharmacogenomics. Results of pathway analysis and more in general gene set analysis may be easier to replicate across different samples than individual SNPs because sources of heterogeneity or bias (for example, genotyping or imputation errors) are expected to have a lower influence and effect sizes are expected to be higher than for individual SNPs. LD score regression and polygenic risk scoring are recent complementary approaches that are expected to provide a relevant contribution to the study of the polygenic complexity of antidepressant response and the sharing of genetic variants with correlated traits, such as MDD, response to other psychotropic drugs or placebo response.
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